What I have: tirzepatide · forty-two days.
I want a method I can write down and repeat, not a rule of thumb.
I would rather over-engineer this than discover a problem later, within reason.
Which parts of this are load-bearing and which parts are habit?
42 days past a due dose is 6 half-lives at the seven-day half-life this class runs on, which leaves about 1.6 per cent of that dose still circulating. One line of arithmetic: remaining fraction is one half raised to days over half-life, so 0.5^(42÷7) = 0.0156. At 1.6 per cent this is a washout rather than a late dose. 42 days is the scenario the escalation schedule was written for. What the product label says and what the pharmacokinetics say are two different answers here, and the first is the one that governs. Restarting, holding or stepping down after a gap is decided under supervision, and nothing here is medical advice.
Answer first: it depends on the half-life and on how long ago the dose was due, and for a weekly agent the tolerance is much wider than people fear.
If more than two consecutive weekly doses are missed, tolerance to the gastrointestinal effects begins to fade and re-titration from a lower step becomes the sensible approach.
The published guidance for the weekly agents is broadly: if the missed dose is remembered within about five days, take it and continue on the usual day; if more than five days have passed, skip it and take the next scheduled dose.
Published missed-dose guidance for the weekly agents in this class specifies a window of about five days, derived directly from the half-life.
The caveat is that anyone on other glucose-lowering medication has an interaction question here that needs a prescriber.
Within about five days for a weekly agent, take it. Beyond that, skip and resume.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsAnswering this needs the agent, since the answer for a thirteen-hour half-life and a one-week half-life are entirely different.
With a one-week half-life dosed weekly, missing one dose means exposure falls by about half over the following week — the same trough you would reach if you simply extended the interval. That is well within the range the agent operates in.
Never take two doses close together to compensate. The peak exposure is roughly doubled, and gastrointestinal tolerability tracks peak exposure closely.
Nothing here is medical advice, and research-use compounds are not approved for human use.
To move your dosing day, move it later and keep three days between doses.
The short version: for a weekly agent, take it if you are within a few days; if you are close to the next scheduled dose, skip it and resume.
For a daily agent with a thirteen-hour half-life, a missed dose is a much larger proportional loss. The usual approach is to skip it and take the next scheduled one rather than doubling.
To be exact about it, to change your regular dosing day, move the next dose later rather than earlier, keeping at least three days between doses for a weekly agent. Moving earlier compresses the interval and raises exposure.
Loss of tolerance during a treatment gap is documented and is the basis for re-titration after an interruption.
Two or more missed weekly doses means considering a lower restarting step.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.